About Champions Oncology (NASDAQ:CSBR)
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company's TumorBank.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:CSBR
- CUSIP: N/A
- Web: www.championsoncology.com
- Current Ratio: 0.57%
- Quick Ratio: 0.57%
Sales & Book Value:
- Annual Sales: $15.41 million
- Price / Sales: 2.60
- Book Value: $0.04 per share
- Price / Book: 91.00
- Trailing EPS: ($0.46)
- Net Income: ($6,880,000.00)
- Net Margins: -29.87%
- Return on Equity: -338.01%
- Return on Assets: -66.70%
- Employees: 79
- Outstanding Shares: 10,990,000
Frequently Asked Questions for Champions Oncology (NASDAQ:CSBR)
What is Champions Oncology's stock symbol?
Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."
How were Champions Oncology's earnings last quarter?
Champions Oncology, Inc. (NASDAQ:CSBR) issued its earnings results on Thursday, September, 14th. The biotechnology company reported ($0.06) EPS for the quarter. The biotechnology company had revenue of $5.03 million for the quarter. Champions Oncology had a negative return on equity of 338.01% and a negative net margin of 29.87%. View Champions Oncology's Earnings History.
When will Champions Oncology make its next earnings announcement?
Who are some of Champions Oncology's key competitors?
Some companies that are related to Champions Oncology include Navidea Biopharmaceuticals (NAVB), Vernalis plc (VER), Tissue Regenix Group PLC (TRX), Abzena PLC (ABZA), NovaBay Pharmaceuticals (NBY), OncoSec Medical Incorporated (ONCS), CytRx Corporation (CYTR), Senomyx (SNMX), OvaScience (OVAS), Aptose Biosciences (APTO), Prima BioMed Ltd (PBMD), Ohr Pharmaceuticals (OHRP), Genocea Biosciences (GNCA), Bio-Path Holdings (BPTH), AEterna Zentaris (AEZS), Oncobiologics (ONS), Prana Biotechnology Ltd (PRAN) and Caladrius Biosciences (CLBS).
Who are Champions Oncology's key executives?
Champions Oncology's management team includes the folowing people:
- Joel Ackerman, Chairman of the Board (Age 51)
- Ronnie Morris M.D., President, Chief Executive Officer, Director (Age 49)
- David Miller CPA, Vice President - Finance (Age 46)
- Philip Breitfeld, Chief Strategic and Innovation Officer, Director (Age 63)
- David Sidransky M.D., Lead Independent Director (Age 56)
- Daniel N. Mendelson, Independent Director (Age 52)
- Abba David Poliakoff, Independent Director (Age 64)
- Scott R. Tobin, Independent Director (Age 45)
Who owns Champions Oncology stock?
Champions Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.52%). Company insiders that own Champions Oncology stock include Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.
Who bought Champions Oncology stock? Who is buying Champions Oncology stock?
Champions Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Champions Oncology stock in the last two years include Joel Ackerman and Ronnie Morris. View Insider Buying and Selling for Champions Oncology.
How do I buy Champions Oncology stock?
Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Champions Oncology's stock price today?
One share of Champions Oncology stock can currently be purchased for approximately $3.64.
How big of a company is Champions Oncology?
Champions Oncology has a market capitalization of $38.02 million and generates $15.41 million in revenue each year. The biotechnology company earns ($6,880,000.00) in net income (profit) each year or ($0.46) on an earnings per share basis. Champions Oncology employs 79 workers across the globe.
How can I contact Champions Oncology?
MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]
Analysts' Consensus Ratings for Champions Oncology (NASDAQ:CSBR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|Consensus Price Target History for Champions Oncology (NASDAQ:CSBR)
Analysts' Ratings History for Champions Oncology (NASDAQ:CSBR)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Champions Oncology (NASDAQ:CSBR)Earnings History by Quarter for Champions Oncology (NASDAQ CSBR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/14/2017||Q1 2018||($0.06)||$5.03 million||View||N/A|
|7/27/2017||Q4 2017||($0.22)||$3.72 million||View||N/A|
|3/16/2017||Q3 2017||($0.13)||$3.57 million||View||N/A|
|11/29/2016||Q2 2017||($0.05)||$4.46 million||View||N/A|
|3/15/2016||Q316||($0.21)||$1.80 million||$2.60 million||View||Listen|
Earnings Estimates for Champions Oncology (NASDAQ:CSBR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Champions Oncology (NASDAQ:CSBR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Champions Oncology (NASDAQ CSBR)
Insider Ownership Percentage: 44.30%Insider Trades by Quarter for Champions Oncology (NASDAQ CSBR)
Institutional Ownership Percentage: 37.93%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/21/2016||Ronnie Morris||President||Buy||30,000||$1.66||$49,800.00|| |
|10/19/2016||Ronnie Morris||President||Buy||10,000||$1.70||$17,000.00|| |
|10/18/2016||Joel Ackerman||CEO||Buy||2,000||$1.70||$3,400.00|| |
|10/14/2016||Joel Ackerman||CEO||Buy||7,300||$1.67||$12,191.00|| |
|10/14/2016||Ronnie Morris||President||Buy||10,305||$1.66||$17,106.30|| |
|10/13/2016||Ronnie Morris||President||Buy||29,695||$1.67||$49,590.65|| |
|10/10/2016||Ronnie Morris||President||Buy||9,537||$1.66||$15,831.42|| |
|10/7/2016||Joel Ackerman||CEO||Buy||8,202||$1.63||$13,369.26|| |
|9/23/2016||Joel Ackerman||CEO||Buy||33||$1.65||$54.45|| |
|9/21/2016||Joel Ackerman||CEO||Buy||5,000||$1.66||$8,300.00|| |
|9/20/2016||Ronnie Morris||President||Buy||3,000||$1.58||$4,740.00|| |
|3/11/2015||Michael Maurice Brown||Major Shareholder||Buy||6,250,000||$0.40||$2,500,000.00|| |
|3/20/2014||Daniel Newman Mendelson||Director||Buy||100,000||$1.08||$108,000.00|| |
|3/19/2014||Ronnie Morris||President||Buy||100,000||$1.07||$107,000.00|| |
|1/28/2013||Michael Maurice Brown||Major Shareholder||Buy||7,000,000||$0.50||$3,500,000.00|| |
|1/28/2013||Ronnie Morris||President||Buy||500,000||$0.50||$250,000.00|| |
Headline Trends for Champions Oncology (NASDAQ:CSBR)
Latest Headlines for Champions Oncology (NASDAQ CSBR)
No headlines for this company have been tracked by MarketBeat.com
Champions Oncology (NASDAQ CSBR) Chart for Friday, November, 17, 2017